**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 54453

**Manuscript Type:** REVIEW

**Metabolomics profile in gastrointestinal cancers: Update and future perspectives**

Nannini G *et al.* NMR metabolomics in GI cancers

Giulia Nannini, Gaia Meoni, Amedeo Amedei, Leonardo Tenori

**Giulia Nannini, Amedeo Amedei,** Department of Experimental and Clinical Medicine, University of Florence, Florence 50134, Italy

**Gaia Meoni,** Giotto Biotech Srl, and CERM (University of Florence), Florence 50019, Italy

**Leonardo Tenori,** Consorzio Interuniversitario Risonanze Magnetiche di Metalloproteine, Florence 50019, Italy

**Amedeo Amedei,** SOD of Interdisciplinary Internal Medicine, Azienda Ospedaliera Universitaria Careggi, Florence 50134, Italy

**Author contributions:** Nannini G and Meoni G were equal contribution to paper writing. Nannini G was involved in the conceptualization, investigation, writing, editing, visualization; Meoni G was involved in the conceptualization, investigation, writing, editing, visualization; Tenori L was involved in writing, review, supervision; Amedei A was involved in writing, review, supervision, funding acquisition. All authors have read and approve the final manuscript.

**Supported by** Foundation “Ente Cassa di Risparmio di Firenze”, No. FCR 2017; and Italian Ministry of Health, Ricerca Finalizzata 2016, No. FR-2016-02361616.

**Corresponding author: Amedeo Amedei, BSc, Associate Professor,** Department of Experimental and Clinical Medicine, University of Florence, Largo Brambilla 3, Florence 50134, Italy. aamedei@unifi.it

**Received:** January 30, 2020

**Revised:** May 11, 2020

**Accepted:** May 15, 2020

**Published online:**

**Abstract**

Despite recent progress in diagnosis and therapy, gastrointestinal (GI) cancers remain one of the most important causes of death with a poor prognosis due to late diagnosis. Serum tumor markers and detection of occult blood in the stool are the current tests used in the clinic of GI cancers; however, these tests are not useful as diagnostic screening since they have low specificity and low sensitivity. Considering that one of the hallmarks of cancer is dysregulated metabolism and metabolomics is an optimal approach to illustrate the metabolic mechanisms that belong to living systems, is now clear that this -omics could open a new way to study cancer. In the last years, nuclear magnetic resonance (NMR) metabolomics has demonstrated to be an optimal approach for diseases' diagnosis nevertheless a few studies focus on the NMR capability to find new biomarkers for early diagnosis of GI cancers. For these reasons in this review, we will give an update on the status of NMR metabolomic studies for the diagnosis and development of GI cancers using biological fluids.

**Key words:** Metabolomics; Nuclear magnetic resonance spectroscopy; Pancreatic cancer; Gastric cancer; Colorectal cancer; Biological fluids

Nannini G, Meoni G, Amedei A, Tenori L. Metabolomics profile in gastrointestinal cancers: Update and future perspectives. *World J Gastroenterol* 2020; In press

**Core tip:** Searching for new tumor biomarkers is essential for the early diagnosis of gastrointestinal tumors. Biofluids could give important data, reducing the need for invasive screening and nuclear magnetic resonance-based metabolomics is an optimal approach to understand metabolic dynamics in biofluids.

**INTRODUCTION**

The continuous increase of the global population, associated with the extended life expectancy, made the cancer one of the main causes of death[1], and for many countries, a very heavy health burden. Despite numerous advances in diagnosis and therapy, gastrointestinal (GI) cancers remain some of the most aggressive cancers for both men and women, as we have previously reported[2]. In particular, the most aggressive types of GI cancers are pancreatic cancer (PC), gastric cancer (GC) and colorectal cancer (CRC). Furthermore, gastric and CRC are respectively in third and fifth place by incidence and even in second and third as regards mortality in both sexes[3]. The GC is one of the most malignant cancers worldwide with a very high rate in Asia[4]. Unfortunately, most cases of GC are diagnosed in the advanced stages with consequent poor prognosis[5]. The epidemiological and molecular feature of GC differ according to the histological type and cancer location. Currently there are several methods for diagnosing GC; however, there are no standardized guidelines[6]. Regarding CRC, it is one of the most diagnosed neoplasms in the world, both among men and women, and is the third most common malignancy[7]. 5-year survival can reach 90% if the tumor is diagnosed at an early stage and is localized, but survival decreases significantly if the tumor is diagnosed late and is spread to other organs[8]. To date, the fecal occult blood and the serum tumor-associated markers are the test commonly used in the clinic; however, the lack of sensitivity and specificity of these markers limits their application in the CRC diagnosis[9,10]. Lastly, PC is one of the most aggressive cancers, with 5-year survival rates of only 5%. PC is currently ranked as the fourth leading cause of cancer-related deaths in the United States and is estimated to be the second leading cause of such fatalities by the year 2020[7]. Mortality is mainly due to late diagnosis because the PC symptoms (such as nausea, weight loss, weariness, abdominal pain) are not disease-specific[11,12]. PC is diagnosed by resonance, computed tomography, endoscopic retrograde cholangiopancreatography and endoscopic ultrasound[13].

For the clinical monitoring of GI cancer, carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 are used as serological tumor-associated markers as well as detection of occult blood in the stool. However, these tests are not currently useful as diagnostic screening as they have low specificity and low sensitivity[14]; but, for the previously reported reasons, the effectiveness of the anti-GI cancers’ treatments depends on an early diagnosis. Based on clinical characteristics, different models for various cancers have been developed to assess the causal risk, however although the results may seem significant at the population level, they have a low predictive value when considering the individual patient[15].

A growing number of studies have suggested that the GI metabolites regulate pathogen infection in the different intestinal sections, through genome-based analysis of bacteria and especially by high-throughput metabolomics[16-18]. Many metabolites affect the cell adhesion and biofilm formation; for example, the D-amino acids produced by *Bacillus subtilis* prevent biofilm formation[19]. In addition, recent studies have revealed a major role of metabolites in the regulation of the immune system taking part in the modulation of the adaptive immune cell development, in particular T lymphocytes[20], which have a crucial role in the genesis of the above-mentioned GI tumors. As we have reported in previous studies, the PC as well as gastric and CRC, show an altered specific immune response characterized by a decreased number of effective T cells[21-23].

One of the hallmarks of cancer is dysregulated metabolism, during which cancer cells show increased glucose uptake and produce lactate. This process is named the “Warburg effect”, but how and why cancer cells reprogram their metabolic state is not well understood. Several metabolic changes associated with cancer can be linked to cellular growth; in fact, the biosynthesis of lipids, proteins, nucleic acids are required for tumor formation and survival. In most cases the expression of oncogenes or the loss of tumor suppressors lead to changes in the metabolism, by expression, activity or flow of the main metabolic pathways. Numerous components of glucose and glutamine (Gln) metabolism have emerged as important regulators of cancer metabolism. Considering the importance of metabolic changes in the development and cancer prognosis, the metabolomics represents a fundamental –omics’ study, as it can be used to evaluate (assess) the alterations of the main metabolites[14]. It is now clear that the metabolic characteristics of cancer cells change with the disease progression[24,25] and typical metabolic changes include deregulated absorption of amino acids and glucose, increased nitrogen demand and increased use of anabolic metabolic pathways[26]. This metabolic reprogramming can be useful for the diagnosis of tumors at an early stage and biological fluids could give important information, reducing the need for invasive screening. Urine and blood are easily accessible matrix that could be used to identify possible biomarkers associated with cancer risk, presence and prognosis, using nuclear magnetic resonance (NMR) analysis[27]. Blood passes through every organ of the human body, acting as a transport for secreted/excreted molecules (in response to physiological stimuli or stress), while urine contains molecules eliminated by renal filtration[28,29]. Furthermore, there are a lot of evidence suggesting that microbial metabolism by gut microbiota produces a variety of compounds, including fatty acids, indole and vitamin K, many of which have toxic effects on the lumen and contribute to the GI carcinogenesis, especially for CRC. In addition, there are many evidence (essentially in experimental models) that suggest a role of the intestinal microbiome in the PC carcinogenesis. Finally, a growing number of microbiome researchers are recognizing that considerable information could be gained by using a more integrative approach that also includes comprehensive fecal metabolite analysis. Feces contain many molecules that reflect nutrient ingestion, digestion and absorption by gut bacteria and GI tract. The dry fecal matter consists of bacterial biomass (25%-54%), exfoliated colonic epithelial cells, undigested food residues (fiber, protein, DNA, mucopolysaccharides, *etc.*) and small molecules or metabolites such as sugars, organic acids, and amino acids. These small molecules compose fecal metabolome.

There is an increasing interest to use metabolomic based approaches to investigate cancer metabolism. The two majors’ instrumental metabolomic techniques are NMR and mass spectrometry (MS). The advantages of these two techniques are intrinsically different. MS platform provides sensitivity and selectivity for metabolomics research, while NMR provides a very high reproducibility, it is quantitative and requires minimal steps for sample preparation allowing to avoid separation or derivatization[30]. Due to the possible impact that NMR-based metabolomics performed using easily accessible biofluids could have on the standard clinical practice of cancer diagnosis, prognosis and risk evaluation, this review aims to be a comprehensive overview of the literature available to date in this restricted, but promising field. Conversely, the use of MS based techniques or the metabolomic analysis of cells, tissues and animal models is reported elsewhere[31,32]. Interestingly, while *e.g.*, breast cancer has been extensively investigated using NMR-based metabolomics of systemic biofluids (especially for relapse risk prediction)[33], for GI cancers this field still appears in its infancy. In this review, we will give an update on the current status of NMR metabolomics’ studies for the diagnosis of GI cancers, discussing the suitability of the different biological samples used and the future perspectives for this analytical approach (Figure 1).

**METABOLIC ALTERATIONS IN GI CANCERS**

Warburg effect is a shift from adenosine triphosphate (ATP) synthesis by oxidative phosphorylation to ATP generation through glycolysis, also in aerobic condition[34]. Tumor cells obtained a large amount of their energy from aerobic glycolysis, converting glucose to lactate instead of metabolizing it in the mitochondria through oxidative phosphorylation. Therefore, in terms of ATP production per glucose molecule consumed, glycolysis is less efficient than oxidative phosphorylation. This metabolic change forces tumor cells to demand a large glucose amount to satisfy their increased energy, biosynthesis and redox needs. In details, lactate accumulation elicits acidic microenvironment, protective for cancer. The presence of lactic acid induces, in cancer cells, the expression of glycolytic enzymes such as 6-phosphofructokinase 1 (PFK1) to: (1) increase the ATP provisions; (2) escape from the cell apoptosis mechanism; and (3) promote angiogenetic mechanisms, providing in this way a comfortable microenvironment for cancer development and metastasis[35]. Abnormal glucose metabolism in GC, with high levels in serum of 3-hydroxypropionic acid and pyruvic acid, may be involved to tumor proliferation leading to aggressive cancer cell proliferation, which needed a large ATP amount, causing, in turn, abnormal levels of intermediate glucose metabolism[36,37].

In PC, abnormal metabolism depends by cellular factors on the anomalous activity of some oncogenes that change the physiological nutrients consumption[38]. In addition, the metabolic reorganization is carried out by the activation of alterations in genes and oncogenic signaling pathways. In fact, some studies show that mutations of *K-RAS* and other oncogenes (and tumor suppressors) represent the key that leads to an acceleration of PC growth by reprogramming directly cellular metabolism[39,40]. It is now assured that the *K-RAS* gene has a crucial role in PC glucose metabolism. An excessive glucose uptake and overexpression of glycolytic enzymes, including type 1 glucose transporter, hexokinase 1/2, phosphofructokinase and lactate dehydrogenase A[41,42] characterize the PC. For all these reasons, lactate is an important “performer” for tumor-connective tissue and energy trade in cellular compartments around cancer microenvironment. In addition, the acidity of the microenvironment helps to repress immune system by promoting chronic inflammation and by suppressing the adaptive immune response[43] leading by T cells.

Also, in CRC, in response to hypoxia, the expression of the glucose transporter 1 is upregulated in neoplastic cells, inducing the enzymes that metabolize glycogen, including glycogen synthase and glycogen phosphorylase. However, altered glycogen metabolism and its potential impact on the CRC biology remain poorly understood[44]. Increasing evidence demonstrated that Gln is an important metabolic substrate and energy source for tumor cells that need Gln for their growth and survival, a dependence called “glutamine addiction”. Recent studies have shown that some cancer cells use Gln to carry out the metabolic processes linked to the cell proliferation and to maintain amino acid levels of the tricarboxylic acid (TCA) cycle, exosamine, nucleotides and other molecules[45,46]. Finally, a new study reports an alternative pathway in the Gln metabolism adopted by PC cells and essential for tumor growth. Usually cells use glutamate dehydrogenase to convert glutamate derived from Gln to α-ketoglutarate in mitochondria in order to use it in the TCA cycle[47,48]. However, the PC feeds the TCA cycles through another pathway, so that the aspartate derived from Gln arrives in the cytoplasm and so, transformed into oxaloacetate *via* aspartatetransaminase (GOT1). The oxaloacetate is then converted into pyruvate at the end of the cycle to increase the ratio between NADPH/NADP + and facilitate the maintenance of the redox state[40].

The growth of cancer cells is strongly based on the possibility of exploiting more autonomous proliferative signaling pathways[49]. PC cells depend strictly on these reactions; in fact, the Gln deprivation or the deactivation of enzymes of this chain of reactions causes an increase in reactive oxygen species and a reduction in reduced glutathione. Finally, the inhibition of the enzymes linked to this cycle reduces the PC growth both *in vitro* and *in vivo*[50].

Lastly, the fatty acid synthase (FASN) is overexpressed in various tumors, showing an important role in cancer onset and progression. Several *in vitro* studies have documented that elevated lipogenesis is correlated with poor prognosis in different tumor types[51]. Lipogenesis is also involved in signal transduction of tumor cells and is increased in tumor tissue and associated with tumor prognosis. Moreover, FASN reduction can promote apoptosis in tumor cells, inhibiting tumor growth and metastasis. Previous studies have demonstrated that FASN is overexpressed in cancer tissue and serum of GC patients. In fact, usually the tumors present enzymes supporting the production of a large number of lipids for the survival and proliferation of neoplastic cells. The tumors need more lipids as energy sources compared to normal cells. Acetyl-CoA carboxylase, the rate-limiting enzyme for the synthesis of fatty acids, if blocked, inhibits the growth and apoptosis of breast, lung and colon cancer cells[52-55].

**METABOLOMICS OF BIO-FLUIDS**

Metabolomics is an optimal approach to describe the metabolic dynamics that reflect the response of living systems to pathophysiological stimuli, genetic modifications and environment factors. Indeed, the comprehensive evaluation of metabolites, the low molecular weight organic molecules involved in all biochemical processes as substrates or products with different specific functions, is fundamental to observe and measure the response of the organism to diverse conditions. In recent years, metabolomics has been widely applied to investigate cancer metabolism. Current platforms for metabolomics are NMR and gas, liquid chromatography, ultra-high-pressure liquid chromatography [GC, liver cancer (LC) and UPLC] and more recently capillary electrophoresis, usually hyphenated to MS. The applications of NMR spectroscopy are not limited to liquid and solid samples but extend to intact tissue samples with the use of high-resolution magic angle spinning NMR spectroscopy. NMR is more reproducible, and it not requires labor‐intensive sample manipulations like fractionation to get quantitative results, while MS is more sensitive than NMR (10-12 mol/L *vs* 10-6 mol/L). Indeed, these two analytical platforms do have a complementary nature[56,57]. One dimensional (1D) proton (1H) NMR approaches are mostly applied in metabolomics studies, offering several advantages thanks to the natural abundance of the 1H isotope (99.9%) and fast experiments under controlled temperature, giving the possibility to exploit the behavior of many molecules reducing the possibility of sample denaturation. 1D NOESY, CPMG (Carr–Purcell–Meiboom–Gill)[58] and 1H diffusion-edited are the most used pulse sequences in metabolomics studies, which permit namely the observation of both low- and relatively high-molecular weight molecules, the low-molecular-weight compounds selectively, and the selective observation of macromolecular components present in the sample. However, some authors prefer to remove the macromolecular components *via* centrifugation. Platforms for the automatic screening of compounds are always under developing, the B.I. platform (Bruker IVDr, Bruker BioSpin) for analysis and quantification lipids ad lipid subfractions in blood samples.

Ultimately, there are different pre-analytical procedures (which also include the storage of the samples) that could affect the sample and it should be taken into account when comparing the findings of different studies[59,60]. Optimal standard operating procedures for pre-analytical handling of blood and urine for metabolomics’ studies and biobanks are well reported by Bernini *et al*[61]. Often 2D spectra for metabolomics studies are required to assign new metabolites, for doubtful cases and metabolite quantification. 2D experiments generally require much longer acquisition times than the standard 1D pulse sequences; therefore, in defining the total acquisition time, one should also consider the stability of the sample under the selected experimental conditions.

Another important aspect of the metabolomic workflow is the use of appropriate statistics to analyze multiparametric data. Most common methods for metabolomic normalization, multivariate and univariate statistical techniques are well reviewed by Vignoli *et al*[56].

NMR based metabolomics has widely demonstrated to be an optimal strategy for diseases’ diagnosis[62-65], classification and prognosis[66] and as previously reported we will give an update on the current status of NMR-based metabolomic studies using biological fluids for the diagnosis of GI cancers. In Table 1we have summarized the different NMR studies evaluated and discussed. Biological samples, are extremely valuable as direct reporters of the diseased region. However, systemic biofluids, such as urine or blood (serum and plasma), but also fecal water, have a slight biochemical correlation with a diseased organ or apparatus, but present two main advantages: the simple, noninvasive or minimally invasive collection, and the ability to reflect the overall response of the patient to the pathological status. On the other hand, urine, blood and fecal water are largely variable in the chemical composition and in number of metabolites, with urine and fecal metabolites being heavily influenced by lifestyle factors such as food and liquid intake, while blood samples show a better-defined and stable metabolome (Figure 2). Detecting and characterizing cancer-associated biomarkers by metabolomics analysis of bio-fluids could make easy and minimally invasive (reducing the collection of tissue biopsies) the diagnostic approach, representing a valid opportunity of success in the early cancer detection. Altered metabolites in the three different biofluid (blood, urine and stool) identified in 21 NMR-based metabolomic studies, were extracted and summarized respectively in Tables 2-4. A total of 46 metabolites were extracted to be significantly altered in blood samples (serum/plasma), 64 in urine and 28 in fecal water of patients with GI cancers, compared to healthy subjects (or controls). Finally, ten publications report the use of NMR metabolomics to study GI cancers on blood samples, seven are based on urine samples and four on stool samples.

***Blood samples***

Serum samples are commonly used in clinic to test the presence of tumor markers such as carcinoembryonic antigen and the carbohydrate antigen 19-9, however these tests have good sensitivity but poor specificity due to the presence of false positive results given by other non-neoplastic condition. Thus, the relevance to develop alternative screening tools improving the early detection and fine defining the cancer classification. Blood metabolomics has demonstrated the potential to help GC diagnosis. OuYang *et al*[67], based on a small cohort of 17 PC patients and 23 healthy subjects showed that entire 1H-NMR serum spectra could be used to discriminate the two groups using principal component analysis (unsupervised multivariate statistical approach), identifying altered levels of 3‐hydroxybutyrate and lactate (Table 2) in PC patients. These alterations were also detected by Zhang *et al*[68] in plasma samples of PC patients (*n* = 19) in parallel to lower levels of citrate, low-density lipoprotein, high-density lipoprotein, valine, lysine, leucine, isoleucine, histidine, glutamine, glutamate, alanine, and higher levels of NAG (N-acetyl glycoproteins), very-low-density lipoprotein, lipid glyceryl, dimethylamine and acetone (Table 2)compared to healthy subjects. Moreover, the authors identified differences in the plasma metabolomic profile of PC patients also compared to chronic pancreatitis patients (*n* = 20). More recently, Michálková *et al*[69], compared the plasma samples of 10 PC patients with ten healthy controls, obtaining an impressive discrimination accuracy (94%). However, this study is based on a very limited sample population and the absence of patients being treated is not specified in the exclusion criteria, which could influence the model accuracy.

Bathe *et al*[70], in a well-designed study, demonstrated the possibility to distinguish PC (*n* = 56) from benign pancreatic conditions (benign masses and chronic pancreatitis) and patients with gallstone disease (*n* = 43), matched by age, jaundice and incidence of diabetes, by NMR metabolomic analysis of serum (AUROC 0.83). Another more recent paper[71] of the same group reported on a bigger monocentric cohort (*n* = 157) the difference in the metabolomic profile of malignant and benign pancreatic and periampullary lesions using 1H-NMR and GC-MS. Indeed, it represents an important finding, since, in the clinic, is not always possible to distinguish PC from other non-pancreatic adenocarcinomas such as periampullary adenocarcinomas, especially when located near to the pancreas’ head. McConnell *et al*[71], used both 1H-NMR and GC-MS to analyzed the metabolomic profile of serum samples of PC patients. Interestingly, comparing the accuracies for the discrimination among patients and controls obtained using the two approaches, it emerges that NMR-based models are more accurate than GC and then NMR-GC combined models (1H-NMR dataset: average of 14 metabolites, AUROC 0.74; GC-MS dataset: average of 18 metabolites, AUROC 0.62; combined CG-MS/1H-NMR datasets: average of 20 metabolites, AUROC 0.66). A similar approach was proposed by Farshidfar *et al*[72] that using metabolomic data obtained from both 1H-NMR and GC-MS platforms, discriminated serum samples of patients with liver-limited metastasis from local (stage II and III) CRC (NMR AUROC 0.88, GC-MS AUROC 0.87) or extrahepatic metastasis patients (NMR AUROC 0.72, GC-MS AUROC 0.90). In a multicentric study with 1H-NMR metabolomic, Bertini *et al*[73] correctly discriminated the serum profile of metastatic CRC patients (regardless of chemotherapy) from healthy subjects (96.7% accuracy). In addition, the authors used the metabolomic profile as an independent predictor of overall survival (OS) obtaining a hazard ratio of 3.37. In particular, short OS patients were characterized by lower serum level of creatine, lipid (-C=C-CH2-C=C-), lipid (-CH=CH-) and valine and higher levels of lipid (-CH2-OCOR) and NAG. Gu *et al*[74] used serum samples to investigate differential metabolomic profile between CRC patients (*n* = 40), colorectal polyp patients (*n* = 32) and healthy controls (*n* = 38). Patients with colon polyps are at high risk for the development of colon cancer, and compared to the metabolism of healthy controls, they found that the major abnormal metabolic pathways were the pyruvate metabolism, glycerolipid metabolism, Gln and glutamate metabolism, and alanine, aspartate and glutamate metabolism. Moreover, they distinguished the metabolomic profile of CRC patients from that of colorectal polyposis (AUROC 0.727). Ghini *et al*[75] raised a very important point about the sample collection by quantifying the effect of preoperative anesthesia on the plasma metabolomic profile of patients with CRC or CRC and LC metastasis. The collection of plasma sample during the preoperative anesthesia is a common procedure that should be avoided in standard metabolomic studies. The authors demonstrated that if compared before the anesthesia CRC *vs* LC can be distinguished using CPMG spectra with an overall classification accuracy of 76.5%, while comparing samples collected during the anesthesia the discrimination accuracy of CRC *vs* LC rose to 90.4%. The increased discrimination was attributed to the authors to the different pharmaceutical treatments administered to CRC patients respect to LC patients.

***Urine samples***

Some NMR-based metabolomic studies are focused on the characterization of the tumor profile in urine samples sometimes considering heterogeneous group of cases (*e.g.*, patients with different cancer stage, metastatic patients, patients with also other cancer types, *etc.*). If not properly considered, these factors represent important confounding elements.

Napoli *et al*[76] proposed a characteristic urinary metabolomics signature of pancreatic ductal adenocarcinoma (PDAC) in a male cohort. However, the selected PDAC group is very heterogeneous, including 12 patients with liver metastasis, 4 diabetic patients and 3 pancreatitis. These effects, together with gender effect, were not examined in the study. Other studies suggested urine as an excellent bio-fluid to monitor the effect of treatment on patients or for the identification of benign form reducing the need for invasive intervention. Davis *et al*[77] demonstrated that using urine sample is possible to discriminate PDAC patients (*n* = 32) from 25 healthy controls (AUROC of 0.988) and from 32 with benign pancreatic disease (AUROC 0.95) with optimal accuracies. They also evaluate the effect of complete surgical resection on metabolomic profile demonstrating a recovering tendency towards the normal profile. The main study criticism is the limited sample size. The results should be validated on a larger cohort. Similarly, urine profile has been investigated by Chan *et al*[78] in a multicentric study to discriminate a group of GC patients (GC, *n* = 43) from patients with benign gastric diseases (*n* = 40), such as gastritis, ulcer, portal hypertensive gastropathy, gastro-oesophageal reflux disease and polyps, and from a group of healthy subjects (*n* = 40). The study described a characteristic GC profile compared to benign gastric disease subjects and HS. However, despite being one of the few multicentric studies, important confounding factors, such as the presence of patients under neoadjuvant and adjuvant therapy in GC group, and the presence of *Helicobacter pylori* positive patients, are not considered. The possibility to use urine profile for the diagnosis of early stage cancer would be a great opportunity and Wang *et al*[79] showed a characteristic urinary metabolomic fingerprint of stage I and stage II CRC patients (stage I/II *vs* stage III/IV: R2Y = 0.41; Q2 = 0.45). Moreover, in this study authors identified both urinary metabolomic differences in early stage CRC samples respect to esophageal cancer, suggesting that upper and lower GI cancers have different metabolomic profiles, and both overlapping metabolites attributable to shared tumorigenesis pathways (disturbed gut microflora and urea metabolism) associated to tumor cells proliferation/growth. However, Wang *et al*[79] did not focus their research on the characterization of the metabolites that differentiate stage I/II from stage III/IV. A recent study[80] proposed the urine NMR metabolomics as a diagnostic method for pre-invasive CRC patients. The authors evaluated the metabolomic profile of advanced adenoma and stage 0 CRC, revealing a high predictive accuracy in the diagnosis of early colorectal neoplasia patients (CRN *vs* healthy subjects: specificity 96.2% and sensitivity 95%). However, case and control groups are not sex matched and the groups used for the comparison are numerically unbalanced; thus, the results obtained should be validated on a larger and balanced court of CRN samples. Urine samples have been studied in GCs research also to evaluate the effect of the treatment on patients. Follow-up urine samples, have been analyzed by Jung *et al*[81] to investigate alterations of urinary markers in GC patients underwent curative surgery. The authors showed that the urinary metabolomic profile has a high predictive value for low- and high-stage GC. Moreover, through the analysis of matched tumour and normal stomach tissues, they found results consistent with those obtained from the urine profile, evidencing an up-regulation of lipid oxidation-related metabolites and amino acids in GC patients (Table 3). Even if limited by a small sample size, Dykstra *et al*[82] published an interesting NMR-based metabolomic study on the topic of personalized medicine in CRC patients. In this retrospective study, authors developed predictor model that is moderately accurate in predicting treatment delay, which depends on reactions to chemotherapy, other medical condition and patient choice. Therefore, the possibility to develop a method capable in predicting it could be important to help clinicians planning for future procedures.

Urinary metabolomic could represent a good non-invasive alternative to determine tumor-associated perturbations and despite the good results of these mentioned retrospective studies, new NMR metabolomic based prospective studies should be performed. The latter, if validated with independent and larger cohorts, could demonstrate the importance of NMR metabolomic for the diagnosis of GI cancers using urine samples. Indeed, urine metabolomic analysis could be easily implemented to be used as wide scale population screening. However, in clinics, the biggest drawback of urine metabolomics’ profile is the variability of the samples, due to different host (*e.g.*, lifestyle and diet) and environmental factors and finally the pathophysiological status of the patients. More attention should be paid during the experimental design to control these variability factors.

***Fecal water***

Despite the rising approval of fecal metabolomics, so far there isn't a standardized method to collect, prepare and analyze fecal samples. This deficiency of standardization is intensifying by the fact that this type of matrix is a semi-solid mixture of endogenous and exogenous components, so a quite complicated sample preparation for metabolomic analyses is required. In addition, fecal metabolite analysis has never been examined through a systematic review or a systematic study, differently from urine, serum, plasma, cerebrospinal fluid, and saliva biofluids. Currently 4 studies take into consideration the metabolic analysis with NMR to quantify the concentration of metabolites in fecal extracts in the CRC, while there are even no works investigating the stool metabolic composition of GC and PC patients. The first study conducted by Monleón *et al*[83] on CRC using a 1H-NMR on a small cohort of 11 controls and 21 CRC patients showed that fecal water extracts have an abundance of small metabolites such as lactate, glucose and amino acids. The spectra exhibited high variability because of the lack of dietary control. Nevertheless, multivariate analysis showed significant differences between the two groups. Similar results were obtained in two different study of Lin *et al*[84,85]. In the first study they investigated the NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in different stages of CRC. In particular, their findings revealed that the fecal metabolic profiles of healthy subjects can be well discriminated from those of even early stage (stage I/II) CRC patients. Moreover, the levels of glucose, lactate, SCFAs, glutamate and succinate at stage I/II differed significantly from those at stage III and IV, giving important molecular information about the staging of CRC. In their second study a total of 70 CRC patients and 70 healthy subjects were enrolled, to rough out the paralleled metabolites of CRC biopsy and the near non neoplastic tissues pre- and postoperative fecal samples from the same patients. This work unveiled distinct and discriminatory metabolites across both matrices of CRC patients, but in particular fecal acetate demonstrated the highest diagnostic performance for discriminating CRC from healthy subjects. In the study of Le Gall *et al*[86], presented a list of fecal metabolites expressed in concentration units among 50 CRC patients and 49 controls. Their results showed that there are significant alterations in the metabolite composition of fecal extracts from patients with CRC compared to controls.

**DISCUSSION**

Early stage GI cancers usually present no symptoms, so are diagnosed at advanced stages with a consequence of poor prognosis. The discovery of predictive biomarkers might lead to early diagnosis with increase in the quality and length of patients' lives. Therefore, the development of low-cost and non-invasive diagnostic techniques is necessary to reduce unfavorable prognosis and medical expenses. In this review, we have reported the results of a series of studies, focusing our survey to NMR-based metabolomic applications in biological fluids, for the discovery of biomarker candidates for GI cancers. The main reason for restricting our analysis to this particular topic stems from the fact that NMR analysis of biofluids is a high throughput, robust, quantitative and reproducible technique that perfectly fits with the concept of large-scale non-invasive population screening. NMR spectra can be easily obtained in a matter of minutes (from 10 to 30 for common fluid samples), and without the need of complex sample pre-treatments. NMR thus offers the possibility to obtain an untargeted and unbiased snapshot of the sample composition, and, with the possibility of quantifying multiple compounds simultaneously, it could become a reference clinical tool for the study of complex biofluids. However, in order to realize in adequate way this approach, it is necessary to standardize both the pre-analytical and the analytical procedures employed for: (1) sample collection; (2) handling, transportation; (3) preparation; and (4) instrumental analysis. In fact, all these steps could affect the composition of the samples and consequently the analysis’ results. The technical specifications for the pre-analytical processes for metabolomics in urine, venous blood serum and plasma have been published by CEN (CEN/TS 16945:2016), following the evidence reported by Bernini *et al*[61]. Unfortunately, these recommendations are still not universally applied. Looking more carefully to the methods employed by the 21 studies considered here, it clearly appears that they are implemented using a variety of machines (spanning from 400 to 800 MHz, being the 600 MHz the most represented), pulse sequences (1D noesy, CPMG, 2D spectra), and number of scans. Therefore, a not perfect match of the results obtained is expected. Furthermore, and more importantly, the cohorts’ composition, even for the same cancer kind, is not exactly the same: *i.e.*, for PC, in some papers the patients are compared with healthy controls, in some other with patients with benign masses or with other diseases. The same is true for CRC (where the controls are healthy subjects or patients with polyposis) and for GC (where the controls are healthy subjects and patients with benign lesions). In any case, the main limitation that emerges from the analysis of the selected papers is the small sample size generally employed. The larger study[73] involves 297 participants (153 CRC and 139 HS), the smallest[69] only 20 participants (10 PC and 10 HS), with the others ranging from few tens to a bit more than one hundred participants. Consequently, the statistical power is quite limited, with a not negligible probability of spurious or not reproducible results. Moreover, almost all the studies are monocentric with cohorts recruited in Asia (China), North America (Canada), and Europe (Denmark, Czech Republic, Spain). Only two papers[75,78] involved multicentric cohorts. The consequence is that, due to the known influence of dietary habits and genetic background on the metabolic profile, the results could be not immediately compared due to the broad geographical distribution of the study cohorts. However, all these limitations can be considered also a strength: if from these different study designs and cohorts emerge some similar results or trends, they can be considered robust enough to be further investigated as candidate biomarkers for GI cancers.

In other words, carefully looking at the results of the 21 evaluated studies, we can identify some common alterations (Figure 3).

Three studies on blood reported that 3-hydroxybutyric acid was present in higher amount in CRC cancer[73,75,87] while results on PC are discordant. 3-Hydroxybutyrate is a ketone body and one of its main functions is to provide acetoacetyl-CoA and acetyl-CoA for the synthesis of cholesterol and lipids. 3-hydroxybutyrate amount in blood increases as oxidation levels increase. Its overexpression could lead to an enhanced lipogenesis promoting tumor growth. Moreover, tyrosine levels in blood samples were concordantly lower in three CRC based studies[73-75]. Several other published studies report the same results; however, the tyrosine[88,89] role has not yet been clarified.

Instead, for what concern the five reported PC cancer studies, only Gln level in blood was found concordant in more than two studies[68,70,81]. Gln plays an important role in regulating redox homeostasis[90]. Cancer cells show an increase Gln demand as the result of a shift from glucose oxidation to “Warburg effect”.

Compared to blood, urine has the main advantages of being non-invasive and available in large amounts. Nevertheless, its natural abundance of metabolites and its high variability among patients makes it difficult bio-fluids to analyze. Among all the mentioned studies, it does not emerge a common biomarker(s) describing a metabolic alteration due to GI. This could be ascribed firstly to the sample variability and secondly to the different tumors and disease stage. Several other factors such as gender, age, hormonal status, diet, or physical activity should be taken into account. Moreover, in some cases it is important to evaluate the effect of patients’ comorbidities, such as diabetes in the PC, where it may be either a risk factor or a symptom.

Higher glucose level in urine of PC patients, identified by Napoli *et al*[76] and Davis *et al*[77] could be due to the presence of diabetic patients in the group of cases, which were not excluded from both studies.

Trigonelline too, was identified in lower amount in PC by both studies. Its presence may be related to particular dietary products (*e.g.*, coffee, tea *etc.*) but may also arise from endogenous niacin methylation. However, some of the identified variations in urine could also be attributed to the interaction of the host with the gut-microflora such as lower hippurate levels, identified in urine of CRC patients by Wang *et al*[79] and Kim *et al*[80], supporting what previously seen that CRC is associated with an altered intestinal microbial composition[91].

Fecal water extract, like urine, can be an interesting bio-specimens due to its non-invasive collection. However, at present there are not studies in literature considering the NMR analysis of these bio-fluids in PC and GC patients. Three of the four studies that we have analyzed[83-85] find common alteration of 3 metabolites: acetate, butyrate, and leucine. Acetate and butyrate are short chain fatty acids (SCFAs), a microbial-derived metabolite, normally produced by the gut bacteria. SCFAs are absorbed by the intestinal epithelium and used as energy sources for intestinal barrier protection[92,93]. The depletion of SCFAs, especially butyrate, in feces could suggest that there has been an intestinal dysbiosis in CRC patients and consequently an alteration in bacterial products[94-96]. Acetate is a precursor molecule for endogenous cholesterol and can be transformed to acetyl-CoA for lipid biosynthesis. This data confirms that the shift to lipogenesis is a typical change of cancer metabolism. Acetate is probably the most discriminative metabolites of SCFAs in the three studies, and in particular Lin and his group find a link between acetate levels in CRC feces and glucose and myo-inositol levels in colorectal tumor tissues. Significant depletions of glucose and myo-inositol in CRC tissues and decrease of acetate levels in feces could be indicative of an increased energy demand by cancer cells for their growth. Compared to healthy subjects an increase of leucine is reported in the feces of CRC patients, this could be due to the epithelium inflammation that leads to malabsorption of nutrients[97]. However, the amino acid metabolic profile is often very varied as there is no dietary control in patients.

**CONCLUSION**

Summarizing the results of the selected studies, we can conclude that NMR analysis of bio-fluids could be a high throughput, quantitative and reproducible test that fully fits with the concept of large-scale non-invasive population screening for the GI cancers. To date, there is small the number of studies exploring this opportunity and focusing only on the patients with CRC and in addition using a restricted number of patients and the same country. Therefore, future perspectives are to plan multicentric studies involving a high number of patients and evaluating not only CRC patients but also patients with pancreatic or GC. In addition, a crucial point will have to be the evaluation of interfering factors such as gender, age, hormonal status, diet, physical activity and especially comorbidities and the metabolites associated with gut microbiota, such as the SCFAs. Finally, despite the restricted number of the studies using the stool for the metabolic NMR analysis, we think that the fecal water samples could be an interesting and cheap bio-fluid to explore for future applications.

**ACKNOWLEDGEMENTS**

The authors thank Dr. Federico Boem, Post Doc for his English language revision.

**REFERENCES**

1 **Bray F**, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; **68**: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]

2 **Amedei A**, Niccolai E, D'Elios MM. T cells and adoptive immunotherapy: recent developments and future prospects in gastrointestinal oncology. *Clin Dev Immunol* 2011; **2011**: 320571 [PMID: 22110523 DOI: 10.1155/2011/320571]

3 **Global Burden of Disease Cancer Collaboration**, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, Dandona L, Fleming T, Forouzanfar MH, Hancock J, Hay RJ, Hunter-Merrill R, Huynh C, Hosgood HD, Johnson CO, Jonas JB, Khubchandani J, Kumar GA, Kutz M, Lan Q, Larson HJ, Liang X, Lim SS, Lopez AD, MacIntyre MF, Marczak L, Marquez N, Mokdad AH, Pinho C, Pourmalek F, Salomon JA, Sanabria JR, Sandar L, Sartorius B, Schwartz SM, Shackelford KA, Shibuya K, Stanaway J, Steiner C, Sun J, Takahashi K, Vollset SE, Vos T, Wagner JA, Wang H, Westerman R, Zeeb H, Zoeckler L, Abd-Allah F, Ahmed MB, Alabed S, Alam NK, Aldhahri SF, Alem G, Alemayohu MA, Ali R, Al-Raddadi R, Amare A, Amoako Y, Artaman A, Asayesh H, Atnafu N, Awasthi A, Saleem HB, Barac A, Bedi N, Bensenor I, Berhane A, Bernabé E, Betsu B, Binagwaho A, Boneya D, Campos-Nonato I, Castañeda-Orjuela C, Catalá-López F, Chiang P, Chibueze C, Chitheer A, Choi JY, Cowie B, Damtew S, das Neves J, Dey S, Dharmaratne S, Dhillon P, Ding E, Driscoll T, Ekwueme D, Endries AY, Farvid M, Farzadfar F, Fernandes J, Fischer F, G/Hiwot TT, Gebru A, Gopalani S, Hailu A, Horino M, Horita N, Husseini A, Huybrechts I, Inoue M, Islami F, Jakovljevic M, James S, Javanbakht M, Jee SH, Kasaeian A, Kedir MS, Khader YS, Khang YH, Kim D, Leigh J, Linn S, Lunevicius R, El Razek HMA, Malekzadeh R, Malta DC, Marcenes W, Markos D, Melaku YA, Meles KG, Mendoza W, Mengiste DT, Meretoja TJ, Miller TR, Mohammad KA, Mohammadi A, Mohammed S, Moradi-Lakeh M, Nagel G, Nand D, Le Nguyen Q, Nolte S, Ogbo FA, Oladimeji KE, Oren E, Pa M, Park EK, Pereira DM, Plass D, Qorbani M, Radfar A, Rafay A, Rahman M, Rana SM, Søreide K, Satpathy M, Sawhney M, Sepanlou SG, Shaikh MA, She J, Shiue I, Shore HR, Shrime MG, So S, Soneji S, Stathopoulou V, Stroumpoulis K, Sufiyan MB, Sykes BL, Tabarés-Seisdedos R, Tadese F, Tedla BA, Tessema GA, Thakur JS, Tran BX, Ukwaja KN, Uzochukwu BSC, Vlassov VV, Weiderpass E, Wubshet Terefe M, Yebyo HG, Yimam HH, Yonemoto N, Younis MZ, Yu C, Zaidi Z, Zaki MES, Zenebe ZM, Murray CJL, Naghavi M. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. *JAMA Oncol* 2017; **3**: 524-548 [PMID: 27918777 DOI: 10.1001/jamaoncol.2016.5688]

4 **Ferlay J**, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; **136**: E359-E386 [PMID: 25220842 DOI: 10.1002/ijc.29210]

5 **Compare D**, Rocco A, Nardone G. Risk factors in gastric cancer. *Eur Rev Med Pharmacol Sci* 2010; **14**: 302-308 [PMID: 20496539]

6 **Leung WK**, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, Gotoda T, Lin JT, You WC, Ng EK, Sung JJ; Asia Pacific Working Group on Gastric Cancer. Screening for gastric cancer in Asia: current evidence and practice. *Lancet Oncol* 2008; **9**: 279-287 [PMID: 18308253 DOI: 10.1016/S1470-2045(08)70072-X]

7 **Siegel RL**, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin* 2018; **68**: 7-30 [PMID: 29313949 DOI: 10.3322/caac.21442]

8 **Siegel R**, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013; **63**: 11-30 [PMID: 23335087 DOI: 10.3322/caac.21166]

9 **Weitz J**, Koch M, Debus J, Höhler T, Galle PR, Büchler MW. Colorectal cancer. *Lancet* 2005; **365**: 153-165 [PMID: 15639298 DOI: 10.1016/S0140-6736(05)17706-X]

10 **Huerta S**. Recent advances in the molecular diagnosis and prognosis of colorectal cancer. *Expert Rev Mol Diagn* 2008; **8**: 277-288 [PMID: 18598107 DOI: 10.1586/14737159.8.3.277]

11 **Amedei A**, Niccolai E, Prisco D. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. *Hum Vaccin Immunother* 2014; **10**: 3354-3368 [PMID: 25483688 DOI: 10.4161/hv.34392]

12 **Li HY**, Cui ZM, Chen J, Guo XZ, Li YY. Pancreatic cancer: diagnosis and treatments. *Tumour Biol* 2015; **36**: 1375-1384 [PMID: 25680410 DOI: 10.1007/s13277-015-3223-7]

13 **Hanada K**, Okazaki A, Hirano N, Izumi Y, Teraoka Y, Ikemoto J, Kanemitsu K, Hino F, Fukuda T, Yonehara S. Diagnostic strategies for early pancreatic cancer. *J Gastroenterol* 2015; **50**: 147-154 [PMID: 25501287 DOI: 10.1007/s00535-014-1026-z]

14 **Burton C**, Ma Y. Current Trends in Cancer Biomarker Discovery Using Urinary Metabolomics: Achievements and New Challenges. *Curr Med Chem* 2019; **26**: 5-28 [PMID: 28914192 DOI: 10.2174/0929867324666170914102236]

15 **Thrift AP**, Whiteman DC. Can we really predict risk of cancer? *Cancer Epidemiol* 2013; **37**: 349-352 [PMID: 23643191 DOI: 10.1016/j.canep.2013.04.002]

16 **Browne HP**, Neville BA, Forster SC, Lawley TD. Transmission of the gut microbiota: spreading of health. *Nat Rev Microbiol* 2017; **15**: 531-543 [PMID: 28603278 DOI: 10.1038/nrmicro.2017.50]

17 **Hirata SI**, Kunisawa J. Gut microbiome, metabolome, and allergic diseases. *Allergol Int* 2017; **66**: 523-528 [PMID: 28693971 DOI: 10.1016/j.alit.2017.06.008]

18 **Kunisawa J**, Hashimoto E, Ishikawa I, Kiyono H. A pivotal role of vitamin B9 in the maintenance of regulatory T cells in vitro and in vivo. *PLoS One* 2012; **7**: e32094 [PMID: 22363800 DOI: 10.1371/journal.pone.0032094]

19 **Mühlen S**, Dersch P. Anti-virulence Strategies to Target Bacterial Infections. *Curr Top Microbiol Immunol* 2016; **398**: 147-183 [PMID: 26942418 DOI: 10.1007/82\_2015\_490]

20 **Levy M**, Blacher E, Elinav E. Microbiome, metabolites and host immunity. *Curr Opin Microbiol* 2017; **35**: 8-15 [PMID: 27883933 DOI: 10.1016/j.mib.2016.10.003]

21 **Amedei A**, Niccolai E, Della Bella C, Cianchi F, Trallori G, Benagiano M, Bencini L, Bernini M, Farsi M, Moretti R, Del Prete G, D'Elios MM. Characterization of tumor antigen peptide-specific T cells isolated from the neoplastic tissue of patients with gastric adenocarcinoma. *Cancer Immunol Immunother* 2009; **58**: 1819-1830 [PMID: 19319530 DOI: 10.1007/s00262-009-0693-8]

22 **Niccolai E**, Taddei A, Ricci F, Rolla S, D'Elios MM, Benagiano M, Bechi P, Bencini L, Ringressi MN, Pini A, Castiglione F, Giordano D, Satolli MA, Coratti A, Cianchi F, Bani D, Prisco D, Novelli F, Amedei A. Intra-tumoral IFN-γ-producing Th22 cells correlate with TNM staging and the worst outcomes in pancreatic cancer. *Clin Sci (Lond)* 2016; **130**: 247-258 [PMID: 26590104 DOI: 10.1042/CS20150437]

23 **Niccolai E**, Ricci F, Russo E, Nannini G, Emmi G, Taddei A, Ringressi MN, Melli F, Miloeva M, Cianchi F, Bechi P, Prisco D, Amedei A. The Different Functional Distribution of "Not Effector" T Cells (Treg/Tnull) in Colorectal Cancer. *Front Immunol* 2017; **8**: 1900 [PMID: 29375559 DOI: 10.3389/fimmu.2017.01900]

24 **Aboagye EO**, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. *Cancer Res* 1999; **59**: 80-84 [PMID: 9892190]

25 **Teahan O**, Bevan CL, Waxman J, Keun HC. Metabolic signatures of malignant progression in prostate epithelial cells. *Int J Biochem Cell Biol* 2011; **43**: 1002-1009 [PMID: 20633696 DOI: 10.1016/j.biocel.2010.07.003]

26 **Pavlova NN**, Thompson CB. The Emerging Hallmarks of Cancer Metabolism. *Cell Metab* 2016; **23**: 27-47 [PMID: 26771115 DOI: 10.1016/j.cmet.2015.12.006]

27 **Wijeyesekera A**, Selman C, Barton RH, Holmes E, Nicholson JK, Withers DJ. Metabotyping of long-lived mice using 1H NMR spectroscopy. *J Proteome Res* 2012; **11**: 2224-2235 [PMID: 22225495 DOI: 10.1021/pr2010154]

28 **Berger D**. A brief history of medical diagnosis and the birth of the clinical laboratory. Part 1--Ancient times through the 19th century. *MLO Med Lab Obs* 1999; **31**: 28-30, 32, 34-40 [PMID: 10539661]

29 **Berger D**. A brief history of medical diagnosis and the birth of the clinical laboratory. Part 2--Laboratory science and professional certification in the 20th century. *MLO Med Lab Obs* 1999; **31**: 32-34, 36, 38 [PMID: 10558024]

30 **Emwas AH**. The strengths and weaknesses of NMR spectroscopy and mass spectrometry with particular focus on metabolomics research. *Methods Mol Biol* 2015; **1277**: 161-193 [PMID: 25677154 DOI: 10.1007/978-1-4939-2377-9\_13]

31 **Turano P**. Colorectal cancer: the potential of metabolic fingerprinting. *Expert Rev Gastroenterol Hepatol* 2014; **8**: 847-849 [PMID: 25109498 DOI: 10.1586/17474124.2014.945912]

32 **Xiao S**, Zhou L. Gastric cancer: Metabolic and metabolomics perspectives (Review). *Int J Oncol* 2017; **51**: 5-17 [PMID: 28535006 DOI: 10.3892/ijo.2017.4000]

33 **McCartney A**, Vignoli A, Biganzoli L, Love R, Tenori L, Luchinat C, Di Leo A. Metabolomics in breast cancer: A decade in review. *Cancer Treat Rev* 2018; **67**: 88-96 [PMID: 29775779 DOI: 10.1016/j.ctrv.2018.04.012]

34 **Warburg O,** Posener K, Negelein E. Ueber den Stoffwechsel der Tumoren. *Biochem Zeitschrift* 1924; **152**: 319-344

35 **Doherty JR**, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. *J Clin Invest* 2013; **123**: 3685-3692 [PMID: 23999443 DOI: 10.1172/JCI69741]

36 **Ikeda A**, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M. Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. *Biomed Chromatogr* 2012; **26**: 548-558 [PMID: 21773981 DOI: 10.1002/bmc.1671]

37 **Song H**, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY. Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. *Braz J Med Biol Res* 2012; **45**: 78-85 [PMID: 22124703 DOI: 10.1590/s0100-879x2011007500158]

38 **Hezel AF**, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. *Genes Dev* 2006; **20**: 1218-1249 [PMID: 16702400 DOI: 10.1101/gad.1415606]

39 **DeBerardinis RJ**, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. *Cell Metab* 2008; **7**: 11-20 [PMID: 18177721 DOI: 10.1016/j.cmet.2007.10.002]

40 **Cetinbas NM**, Sudderth J, Harris RC, Cebeci A, Negri GL, Yılmaz ÖH, DeBerardinis RJ, Sorensen PH. Glucose-dependent anaplerosis in cancer cells is required for cellular redox balance in the absence of glutamine. *Sci Rep* 2016; **6**: 32606 [PMID: 27605385 DOI: 10.1038/srep32606]

41 **Ying H**, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL, Yan H, Wang W, Chen S, Viale A, Zheng H, Paik JH, Lim C, Guimaraes AR, Martin ES, Chang J, Hezel AF, Perry SR, Hu J, Gan B, Xiao Y, Asara JM, Weissleder R, Wang YA, Chin L, Cantley LC, DePinho RA. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. *Cell* 2012; **149**: 656-670 [PMID: 22541435 DOI: 10.1016/j.cell.2012.01.058]

42 **Wang CW**, Purkayastha A, Jones KT, Thaker SK, Banerjee U. In vivo genetic dissection of tumor growth and the Warburg effect. *Elife* 2016; **5** [PMID: 27585295 DOI: 10.7554/eLife.18126]

43 **Choi SY**, Collins CC, Gout PW, Wang Y. Cancer-generated lactic acid: a regulatory, immunosuppressive metabolite? *J Pathol* 2013; **230**: 350-355 [PMID: 23729358 DOI: 10.1002/path.4218]

44 **Vyas M**, Patel N, Celli R, Wajapeyee N, Jain D, Zhang X. Glucose Metabolic Reprogramming and Cell Proliferation Arrest in Colorectal Micropapillary Carcinoma. *Gastroenterology Res* 2019; **12**: 128-134 [PMID: 31236153 DOI: 10.14740/gr1145]

45 **Wise DR**, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. *Trends Biochem Sci* 2010; **35**: 427-433 [PMID: 20570523 DOI: 10.1016/j.tibs.2010.05.003]

46 **Altman BJ**, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. *Nat Rev Cancer* 2016; **16**: 619-634 [PMID: 27492215 DOI: 10.1038/nrc.2016.71]

47 **Guo Y**, Deng Y, Li X, Ning Y, Lin X, Guo S, Chen M, Han M. Glutaminolysis Was Induced by TGF-β1 through PP2Ac Regulated Raf-MEK-ERK Signaling in Endothelial Cells. *PLoS One* 2016; **11**: e0162658 [PMID: 27612201 DOI: 10.1371/journal.pone.0162658]

48 **Chan AK**, Bruce JI, Siriwardena AK. Glucose metabolic phenotype of pancreatic cancer. *World J Gastroenterol* 2016; **22**: 3471-3485 [PMID: 27022229 DOI: 10.3748/wjg.v22.i12.3471]

49 **Hanahan D**, Weinberg RA. Hallmarks of cancer: the next generation. *Cell* 2011; **144**: 646-674 [PMID: 21376230 DOI: 10.1016/j.cell.2011.02.013]

50 **Son J**, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, Perera RM, Ferrone CR, Mullarky E, Shyh-Chang N, Kang Y, Fleming JB, Bardeesy N, Asara JM, Haigis MC, DePinho RA, Cantley LC, Kimmelman AC. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. *Nature* 2013; **496**: 101-105 [PMID: 23535601 DOI: 10.1038/nature12040]

51 **Menendez JA**, Colomer R, Lupu R. Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids? *Med Hypotheses* 2005; **64**: 342-349 [PMID: 15607569 DOI: 10.1016/j.mehy.2004.07.022]

52 **Brusselmans K**, De Schrijver E, Verhoeven G, Swinnen JV. RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. *Cancer Res* 2005; **65**: 6719-6725 [PMID: 16061653 DOI: 10.1158/0008-5472.CAN-05-0571]

53 **Li S**, Qiu L, Wu B, Shen H, Zhu J, Zhou L, Gu L, Di W. TOFA suppresses ovarian cancer cell growth in vitro and in vivo. *Mol Med Rep* 2013; **8**: 373-378 [PMID: 23732836 DOI: 10.3892/mmr.2013.1505]

54 **Chajès V**, Cambot M, Moreau K, Lenoir GM, Joulin V. Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. *Cancer Res* 2006; **66**: 5287-5294 [PMID: 16707454 DOI: 10.1158/0008-5472.CAN-05-1489]

55 **Wang C**, Xu C, Sun M, Luo D, Liao DF, Cao D. Acetyl-CoA carboxylase-alpha inhibitor TOFA induces human cancer cell apoptosis. *Biochem Biophys Res Commun* 2009; **385**: 302-306 [PMID: 19450551 DOI: 10.1016/j.bbrc.2009.05.045]

56 **Vignoli A**, Ghini V, Meoni G, Licari C, Takis PG, Tenori L, Turano P, Luchinat C. High-Throughput Metabolomics by 1D NMR. *Angew Chem Int Ed Engl* 2019; **58**: 968-994 [PMID: 29999221 DOI: 10.1002/anie.201804736]

57 **Pan Z**, Raftery D. Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. *Anal Bioanal Chem* 2007; **387**: 525-527 [PMID: 16955259 DOI: 10.1007/s00216-006-0687-8]

58 **Carr HY,** Purcell EM. Effects of Diffusion on Free Precession in Nuclear Magnetic Resonance Experiments. *Phys Rev* 1954; **94**: 630-638 [DOI: 10.1103/PhysRev.94.630]

59 **Ghini V**, Quaglio D, Luchinat C, Turano P. NMR for sample quality assessment in metabolomics. *N Biotechnol* 2019; **52**: 25-34 [PMID: 31022482 DOI: 10.1016/j.nbt.2019.04.004]

60 **Takis PG,** Ghini V, Tenori L, Turano P, Luchinat C. Uniqueness of the NMR approach to metabolomics. *TrAC-Trend Anal Chem* 2019; **120**: 115300 [DOI: 10.1016/j.trac.2018.10.036]

61 **Bernini P**, Bertini I, Luchinat C, Nincheri P, Staderini S, Turano P. Standard operating procedures for pre-analytical handling of blood and urine for metabolomic studies and biobanks. *J Biomol NMR* 2011; **49**: 231-243 [PMID: 21380509 DOI: 10.1007/s10858-011-9489-1]

62 **Meoni G**, Lorini S, Monti M, Madia F, Corti G, Luchinat C, Zignego AL, Tenori L, Gragnani L. The metabolic fingerprints of HCV and HBV infections studied by Nuclear Magnetic Resonance Spectroscopy. *Sci Rep* 2019; **9**: 4128 [PMID: 30858406 DOI: 10.1038/s41598-019-40028-4]

63 **Vignoli A**, Orlandini B, Tenori L, Biagini MR, Milani S, Renzi D, Luchinat C, Calabrò AS. Metabolic Signature of Primary Biliary Cholangitis and Its Comparison with Celiac Disease. *J Proteome Res* 2019; **18**: 1228-1236 [PMID: 30539636 DOI: 10.1021/acs.jproteome.8b00849]

64 **Vignoli A**, Rodio DM, Bellizzi A, Sobolev AP, Anzivino E, Mischitelli M, Tenori L, Marini F, Priori R, Scrivo R, Valesini G, Francia A, Morreale M, Ciardi MR, Iannetta M, Campanella C, Capitani D, Luchinat C, Pietropaolo V, Mannina L. NMR-based metabolomic approach to study urine samples of chronic inflammatory rheumatic disease patients. *Anal Bioanal Chem* 2017; **409**: 1405-1413 [PMID: 27900420 DOI: 10.1007/s00216-016-0074-z]

65 **Ghini V**, Saccenti E, Tenori L, Assfalg M, Luchinat C. Allostasis and Resilience of the Human Individual Metabolic Phenotype. *J Proteome Res* 2015; **14**: 2951-2962 [PMID: 26055080 DOI: 10.1021/acs.jproteome.5b00275]

66 **Vignoli A**, Tenori L, Giusti B, Takis PG, Valente S, Carrabba N, Balzi D, Barchielli A, Marchionni N, Gensini GF, Marcucci R, Luchinat C, Gori AM. NMR-based metabolomics identifies patients at high risk of death within two years after acute myocardial infarction in the AMI-Florence II cohort. *BMC Med* 2019; **17**: 3 [PMID: 30616610 DOI: 10.1186/s12916-018-1240-2]

67 **OuYang D**, Xu J, Huang H, Chen Z. Metabolomic profiling of serum from human pancreatic cancer patients using 1H NMR spectroscopy and principal component analysis. *Appl Biochem Biotechnol* 2011; **165**: 148-154 [PMID: 21505807 DOI: 10.1007/s12010-011-9240-0]

68 **Zhang L**, Jin H, Guo X, Yang Z, Zhao L, Tang S, Mo P, Wu K, Nie Y, Pan Y, Fan D. Distinguishing pancreatic cancer from chronic pancreatitis and healthy individuals by (1)H nuclear magnetic resonance-based metabonomic profiles. *Clin Biochem* 2012; **45**: 1064-1069 [PMID: 22613268 DOI: 10.1016/j.clinbiochem.2012.05.012]

69 **Michálková L**, Horník Š, Sýkora J, Habartová L, Setnička V. Diagnosis of pancreatic cancer via1H NMR metabolomics of human plasma. *Analyst* 2018; **143**: 5974-5978 [PMID: 30270368 DOI: 10.1039/c8an01310a]

70 **Bathe OF**, Shaykhutdinov R, Kopciuk K, Weljie AM, McKay A, Sutherland FR, Dixon E, Dunse N, Sotiropoulos D, Vogel HJ. Feasibility of identifying pancreatic cancer based on serum metabolomics. *Cancer Epidemiol Biomarkers Prev* 2011; **20**: 140-147 [PMID: 21098649 DOI: 10.1158/1055-9965.EPI-10-0712]

71 **McConnell YJ**, Farshidfar F, Weljie AM, Kopciuk KA, Dixon E, Ball CG, Sutherland FR, Vogel HJ, Bathe OF. Distinguishing Benign from Malignant Pancreatic and Periampullary Lesions Using Combined Use of ¹H-NMR Spectroscopy and Gas Chromatography-Mass Spectrometry. *Metabolites* 2017; **7** [PMID: 28098776 DOI: 10.3390/metabo7010003]

72 **Farshidfar F**, Weljie AM, Kopciuk K, Buie WD, Maclean A, Dixon E, Sutherland FR, Molckovsky A, Vogel HJ, Bathe OF. Serum metabolomic profile as a means to distinguish stage of colorectal cancer. *Genome Med* 2012; **4**: 42 [PMID: 22583555 DOI: 10.1186/gm341]

73 **Bertini I**, Cacciatore S, Jensen BV, Schou JV, Johansen JS, Kruhøffer M, Luchinat C, Nielsen DL, Turano P. Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. *Cancer Res* 2012; **72**: 356-364 [PMID: 22080567 DOI: 10.1158/0008-5472.CAN-11-1543]

74 **Gu J**, Xiao Y, Shu D, Liang X, Hu X, Xie Y, Lin D, Li H. Metabolomics Analysis in Serum from Patients with Colorectal Polyp and Colorectal Cancer by 1H-NMR Spectrometry. *Dis Markers* 2019; **2019**: 3491852 [PMID: 31089393 DOI: 10.1155/2019/3491852]

75 **Ghini V**, Unger FT, Tenori L, Turano P, Juhl H, David KA. Metabolomics profiling of pre-and post-anesthesia plasma samples of colorectal patients obtained via Ficoll separation. *Metabolomics* 2015; **11**: 1769-1778 [PMID: 26491424 DOI: 10.1007/s11306-015-0832-5]

76 **Napoli C**, Sperandio N, Lawlor RT, Scarpa A, Molinari H, Assfalg M. Urine metabolic signature of pancreatic ductal adenocarcinoma by (1)h nuclear magnetic resonance: identification, mapping, and evolution. *J Proteome Res* 2012; **11**: 1274-1283 [PMID: 22066465 DOI: 10.1021/pr200960u]

77 **Davis VW**, Schiller DE, Eurich D, Bathe OF, Sawyer MB. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature. *Ann Surg Oncol* 2013; **20 Suppl 3**: S415-S423 [PMID: 23096698 DOI: 10.1245/s10434-012-2686-7]

78 **Chan AW**, Mercier P, Schiller D, Bailey R, Robbins S, Eurich DT, Sawyer MB, Broadhurst D. (1)H-NMR urinary metabolomic profiling for diagnosis of gastric cancer. *Br J Cancer* 2016; **114**: 59-62 [PMID: 26645240 DOI: 10.1038/bjc.2015.414]

79 **Wang Z**, Lin Y, Liang J, Huang Y, Ma C, Liu X, Yang J. NMR-based metabolomic techniques identify potential urinary biomarkers for early colorectal cancer detection. *Oncotarget* 2017; **8**: 105819-105831 [PMID: 29285295 DOI: 10.18632/oncotarget.22402]

80 **Kim ER**, Kwon HN, Nam H, Kim JJ, Park S, Kim YH. Urine-NMR metabolomics for screening of advanced colorectal adenoma and early stage colorectal cancer. *Sci Rep* 2019; **9**: 4786 [PMID: 30886205 DOI: 10.1038/s41598-019-41216-y]

81 **Jung J**, Jung Y, Bang EJ, Cho SI, Jang YJ, Kwak JM, Ryu DH, Park S, Hwang GS. Noninvasive diagnosis and evaluation of curative surgery for gastric cancer by using NMR-based metabolomic profiling. *Ann Surg Oncol* 2014; **21 Suppl 4**: S736-S742 [PMID: 25092158 DOI: 10.1245/s10434-014-3886-0]

82 **Dykstra MA**, Switzer N, Eisner R, Tso V, Foshaug R, Ismond K, Fedorak R, Wang H. Urine metabolomics as a predictor of patient tolerance and response to adjuvant chemotherapy in colorectal cancer. *Mol Clin Oncol* 2017; **7**: 767-770 [PMID: 29142749 DOI: 10.3892/mco.2017.1407]

83 **Monleón D**, Morales JM, Barrasa A, López JA, Vázquez C, Celda B. Metabolite profiling of fecal water extracts from human colorectal cancer. *NMR Biomed* 2009; **22**: 342-348 [PMID: 19006102 DOI: 10.1002/nbm.1345]

84 **Lin Y**, Ma C, Liu C, Wang Z, Yang J, Liu X, Shen Z, Wu R. NMR-based fecal metabolomics fingerprinting as predictors of earlier diagnosis in patients with colorectal cancer. *Oncotarget* 2016; **7**: 29454-29464 [PMID: 27107423 DOI: 10.18632/oncotarget.8762]

85 **Lin Y**, Ma C, Bezabeh T, Wang Z, Liang J, Huang Y, Zhao J, Liu X, Ye W, Tang W, Ouyang T, Wu R. 1 H NMR-based metabolomics reveal overlapping discriminatory metabolites and metabolic pathway disturbances between colorectal tumor tissues and fecal samples. *Int J Cancer* 2019; **145**: 1679-1689 [PMID: 30720869 DOI: 10.1002/ijc.32190]

86 **Le Gall G**, Guttula K, Kellingray L, Tett AJ, Ten Hoopen R, Kemsley EK, Savva GM, Ibrahim A, Narbad A. Metabolite quantification of faecal extracts from colorectal cancer patients and healthy controls. *Oncotarget* 2018; **9**: 33278-33289 [PMID: 30279959 DOI: 10.18632/oncotarget.26022]

87 **Ludwig C**, Ward DG, Martin A, Viant MR, Ismail T, Johnson PJ, Wakelam MJ, Günther UL. Fast targeted multidimensional NMR metabolomics of colorectal cancer. *Magn Reson Chem* 2009; **47 Suppl 1**: S68-S73 [PMID: 19790200 DOI: 10.1002/mrc.2519]

88 **Wiggins T**, Kumar S, Markar SR, Antonowicz S, Hanna GB. Tyrosine, phenylalanine, and tryptophan in gastroesophageal malignancy: a systematic review. *Cancer Epidemiol Biomarkers Prev* 2015; **24**: 32-38 [PMID: 25344892 DOI: 10.1158/1055-9965.EPI-14-0980]

89 **Leichtle AB**, Nuoffer JM, Ceglarek U, Kase J, Conrad T, Witzigmann H, Thiery J, Fiedler GM. Serum amino acid profiles and their alterations in colorectal cancer. *Metabolomics* 2012; **8**: 643-653 [PMID: 22833708 DOI: 10.1007/s11306-011-0357-5]

90 **Bott AJ**, Shen J, Tonelli C, Zhan L, Sivaram N, Jiang YP, Yu X, Bhatt V, Chiles E, Zhong H, Maimouni S, Dai W, Velasquez S, Pan JA, Muthalagu N, Morton J, Anthony TG, Feng H, Lamers WH, Murphy DJ, Guo JY, Jin J, Crawford HC, Zhang L, White E, Lin RZ, Su X, Tuveson DA, Zong WX. Glutamine Anabolism Plays a Critical Role in Pancreatic Cancer by Coupling Carbon and Nitrogen Metabolism. *Cell Rep* 2019; **29**: 1287-1298.e6 [PMID: 31665640 DOI: 10.1016/j.celrep.2019.09.056]

91 **Cheng Y**, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W. Distinct urinary metabolic profile of human colorectal cancer. *J Proteome Res* 2012; **11**: 1354-1363 [PMID: 22148915 DOI: 10.1021/pr201001a]

92 **Trinchieri G**. Cancer and inflammation: an old intuition with rapidly evolving new concepts. *Annu Rev Immunol* 2012; **30**: 677-706 [PMID: 22224761 DOI: 10.1146/annurev-immunol-020711-075008]

93 **Al-Lahham SH**, Peppelenbosch MP, Roelofsen H, Vonk RJ, Venema K. Biological effects of propionic acid in humans; metabolism, potential applications and underlying mechanisms. *Biochim Biophys Acta* 2010; **1801**: 1175-1183 [PMID: 20691280 DOI: 10.1016/j.bbalip.2010.07.007]

94 **Roy CC**, Kien CL, Bouthillier L, Levy E. Short-chain fatty acids: ready for prime time? *Nutr Clin Pract* 2006; **21**: 351-366 [PMID: 16870803 DOI: 10.1177/0115426506021004351]

95 **Hassig CA**, Tong JK, Schreiber SL. Fiber-derived butyrate and the prevention of colon cancer. *Chem Biol* 1997; **4**: 783-789 [PMID: 9384528 DOI: 10.1016/s1074-5521(97)90111-3]

96 **Pouillart PR**. Role of butyric acid and its derivatives in the treatment of colorectal cancer and hemoglobinopathies. *Life Sci* 1998; **63**: 1739-1760 [PMID: 9820119 DOI: 10.1016/s0024-3205(98)00279-3]

97 **Costello LC**, Franklin RB. 'Why do tumour cells glycolyse?': from glycolysis through citrate to lipogenesis. *Mol Cell Biochem* 2005; **280**: 1-8 [PMID: 16511951 DOI: 10.1007/s11010-005-8841-8]

**Footnotes**

**Conflict-of-interest statement:** The authors declare that they have no competing interests.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** January 30, 2020

**First decision:** April 18, 2020

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Italy

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P- Reviewer:** Xu X, Takahashi T **S- Editor:** Dou Y **L- Editor:** **E- Editor:**

**Figure Legends**

****

**Figure 1 Selection of discussed nuclear magnetic resonance-based metabolomics review.** The figure shows the study workflow. First, we searched for metabolomic-based studies, then we limited our research to nuclear magnetic resonance-based metabolomic studies and finally we only selected 21 nuclear magnetic resonance-based metabolomic studies on human bio-fluids, in particular blood, urine and fecal water. NMR: Nuclear magnetic resonance.

****

**Figure 2 Summary of the advantages and disadvantages of various bio-fluids.** The figure shows the advantages and disadvantages linked to the use of the three bio-fluids take into consideration for human nuclear magnetic resonance analyses.

****

**Figure 3 Most significant metabolites identified in the 21 studies analyzed.** We have summarized in the outline the most significant metabolites identified in blood, urine and fecal water in the 21 evaluated studies. The green and the red arrows indicate respectively the increase or decrease of the metabolite detected in colorectal cancer or pancreatic cancer in the corresponding references. CRC: Colorectal cancer; PC: Pancreatic cancer.

**Table 1 List of evaluated studies**



|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Type of tumor** | **Ref.** | **Type of biofluid** | **Sample size** | **Mono- or multi- centric study** | **Cohort allocation** | **NMR (MHz)**  | **Acquisition temperature and pulse sequences** |
| PC | [70] | S | 99 (56 PC; 43 control patients: benign pancreatic masses, pancreatitis and gallstone disease) | Mono | Calgary, Canada | 600  | 298 K, 1D Noesy: 1024 sc; 2D TOCSY, HSQC |
| PC | [67] | S | 30 (17 PC; 23 HS) | Mono | Fuzhou, China | 500  | 298 K, CPMG: 256 sc |
| PC | [68] | P | 59 (19 PC; 20 chronic pancreatitis; 20 HS) | Mono | Xi'an, China | 600  | 298 K, 1D Noesy: 64 sc |
| PC | [71] | S | 157 (122 PC/periampullary cancer; 35 benign pancreatic/periampullary disease) | Mono | Calgary, Canada | 600  | 298 K, 1D Noesy: 1024 sc; 2D TOCSY, HSQC |
| PC | [69] | P | 20 (10 PC; 10 HS) | Mono | Prague, Czech Republic | 500  | 298 K, CPMG: 128 sc |
| CRC | [87] | S | 57 (38 CRC; 19 HS) | Mono | Birmingham, United Kingdom | 800  | CPMG: 128 sc; TOCSY: 32 sc; hadamard-TOCSY: 8 scasc |
| CRC | [73] | S | 297 (153 mCRC; 139 HS) | Multi | Denmark | 600  | 310 K, CPMG: 64 sc; JRES: 1 sc |
| CRC | [72] | S | 112 (42 lCRC; 45 liver metast.; 25 extrahepatic metast.) | Mono | Calgary, Canada | 600  | 298 K, 1D Noesy: 1024 sc; 2D TOCSY, HSQC |
| CRC | [75] | P | 70 (40 CRC; 30 liver metastases from CRC) | Multi | Hamburg, Germany | 600  | 300 K, 1D Noesy, CPMG and Diff: 64 sc each |
| CRC | [74] | S | 110 (40 CRC; 32 colorectal polyp patients; 38 HS) | Mono | Xiamen, China | 600  | 298 K, CPMG: 256 sc |
| PC | [76] | U | 87(33 PDAC; 54 HS) | Mono | Verona, Italy | 600  | 300 K, 1D Noesy 32 sc; JRES and HSQC |
| PC | [77] | U | 89 (32 PDAC; 32 benign; 25 HS) | Mono | Alberta, Canada | 600  | 298 K, 1D Noesy: 32 sc |
| GC | [81] | U | 145 (75 GC; 81 HS) | Mono | Seoul, Korea | 600  | 298 K, 1D Noesy: 64 sc |
| GC | [78] | U | 123 (43 GC, 40 benign gastric disease, 40 HS) | Multi | Alberta, Canada | 600  | 298 K, 1D Noesy: 128 sc |
| CRC | [68] | U | 113 (55 CRC; 18 EC; 40 HS) | Mono | Guangdong, China | 400  | 1D Noesy: 256 sc |
| CRC | [82] | U | 62 CRC | Mono | Alberta, Canada | 600  | 298 K, 1D Noesy: 32 sc |
| CRC | [80] | U | 248 (92 CRC; 156 HS) | Mono | Seoul, Korea | 500  | NA |
| CRC | [83] | ST | 33 (21 CRC; 11 HS) | Mono | Valencia, Spain | 600 | 283 K, CPMG: 256 sc; 2D TOCSY, HSQC |
| CRC | [84] | ST | 100 (68 CRC; 32 HS) | Mono | Guangdong, China | 400 | 298 K, 1D Noesy: 64 sc |
| CRC | [86] | ST | 99 (50 CRC; 49 HS) | Mono | United Kingdom | 600 | 1D Noesy 2816 sc; 2D COSY, HSQC and HMBC |
| CRC | [85] | ST | 140 (70 CRC; 70 HS) | Mono | Guangdong, China | 400 | 298 K, 1D Noesy: 64 sc |

S: Serum, P: Plasma, U: Urine, ST: Stool; PC: Pancreatic cancer; HS: Healthy subjects; CRC: Colorectal cancer; EC: Esophageal cancer; GC: Gastric cancer; lCRC: Locoregional; mCRC: Metastatic colorectal cancer; sc: Number of scans; NA: Not available information.

**Table 2 Panel of altered metabolites’ levels identified in blood samples of gastrointestinal cancer patients *vs* healthy controls**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **S** | **P** | **S** |
| **PC[70]** | **PC[67]** | **PC[71]** | **PC[68]** | **PC[69]** | **CRC[75]** | **CRC[87]** | **CRC[73]** | **CRC[72]** | **CRC[74]** |
| 2-aminobutyrate |  |   |   |   |   |   |   |  | ↓2 |  |
| 2-hydroxyisovalerate |  |   |   |   |   |   |   |  | ↓ |  |
| 2-oxoglutarate |   |   |   |   |   |   |   |  | ↑1 |  |
| 3-hydroxybutyrate | ↑ | ↓ |   | ↓ | ↑ | ↑ | ↑ | ↑ |  |  |
| 3-hydroxyisovalerate |   | ↓ |   |   |   |   |   |  |  |  |
| Acetate |   |   |   |   |   | ↓ | ↑ | ↑ |  |  |
| Acetoacetate |   |   |   |   |   | ↑ | ↑ |  |  |  |
| Acetone | ↑ |   |   | ↑ |   |   |   |  |  |  |
| Alanine |   |   | ↓ | ↓ | ↑ |   |   | ↓ |  | ↓ |
| Arginine |   |   |   |   |   | ↑ |   |  |  |  |
| Asparagine | ↓ |   |   |   |   |   |   |  |  |  |
| Beta-alanine |   |   |   |   |   |   |   |  | ↓ |  |
| Citrate |   |   |   | ↓ |   | ↑ |   | ↓ |  | ↓ |
| Creatine | ↓ |   | ↓ |   |   |   |   | ↓ | ↑ |  |
| Creatinine |   | ↑ |   |   |   |   |   |  |  |  |
| Ethanol | ↓ |   |   |   |   |   |   |  |  |  |
| Formate |   |   |   |   |   |   |   | ↑ | ↓ |  |
| Glucose |   |   |   |   |   |   |   |  |  | ↑ |
| Glutamate | ↑ |   | ↑ | ↓ |   |   |   |  | ↓ | ↑ |
| Glutamine | ↓ |   | ↓ | ↓ | ↑ |   |   | ↓ | ↑ | ↓ |
| Glycerol |   |   |   |   |   |   |   | ↑ | ↑ |  |
| HDL |   |   |   | ↓ |   |   |   |  |  |  |
| Histidine |   |   |   | ↓ |   |   |   |  | ↓ |  |
| Hypoxanthine |   |   |   |   |   |   |   |  | ↑ |  |
| Isobutyrate |   |   |   |   |   |   |   |  | ↓ |  |
| Isoleucine |   | ↑ |   | ↓ |   |   |   |  | ↑ |  |
| Isopropanol |   |   | ↑ |   |   |   |   |  |  |  |
| Lactate |   | ↓ |   | ↓ | ↑ |   | ↑ | ↓ |  |  |
| LDL |   |   |   | ↓ |   |   |   |  |  |  |
| Leucine |   | ↑ |   |   |   |   |   | ↓ |  | ↓ |
| Lysine | ↓ |   | ↓ | ↓ |   |   |   |  |  |  |
| Mannose | ↑ |   | ↑ |   |   |   |   |  | ↑ |  |
| Myo-inositol |   |   | ↑ |   |   |   |   |  |  |  |
| N-acetyl glycoproteins |   |   | ↑ |   |   |   | ↑ |  |  |
| O-phosphocholine |   |   |   |   |   |   |   |  | ↑ |  |
| Ornithine |   |   | ↓ |   |   |   |   |  |  |  |
| Phenylalanine | ↑ |   | ↑ |   |   |   |   | ↑ |  |  |
| Proline |   |   | ↓ |   |   |   |   | ↑ |  | ↓ |
| Pyruvate |   |   |   |   |   |   | ↑ | ↓ |  |  |
| Serine |   |   |   |   |   |   |   |  |  | ↑ |
| Threonine | ↓ |   | ↓ |   |   |   |   |  |  |  |
| TMAO |   | ↓ |   |   |   |   |   |  |  |  |
| Tyrosine |   |   |   |   |   | ↓ |   | ↓ |  | ↓ |
| Urea |   |   | ↑ |   |   |   |   |  |  |  |
| Valine |   |   |   | ↓ | ↑ |   |   | ↓ |  | ↓ |
| VLDL |   |   |   | ↑ |   |   |   |  |  |  |

1↑Higher metabolite levels in gastrointestinal cancers. 2↓Lower metabolite levels in gastrointestinal cancers. HDL: High-density lipoprotein; LDL: Low-density lipoprotein; TMAO: Trimetlylamine oxide; VLDL: Very-low-density lipoprotein; CRC: Colorectal cancer; PC: Pancreatic cancer.

**Table 3 List of altered metabolites’ levels identified in urine samples of gastrointestinal cancer patients *vs* to healthy controls**

|  |  |
| --- | --- |
|  | **U** |
| **PC[76]** | **PC[77]** | **CRC[79]** | **CRC[80]** | **GC[78]** | **GC[81]** |
| 1-methylnicotinamide | ↑1 |   |   | ↓2 | ↓ |
| 2-furoylglycine |  |  |   |   | ↑ |   |
| 2-hydroxyisobutyrate | ↑ |   |   |   |  |
| 2-oxobutyrate |  |  |   |   |   | ↑ |
| 2-phenylacetamide | ↑ |  |   |   |   |  |
| 3-aminoisobutyrate |  |  |   | ↑ |   | ↑ |
| 3-hydroxyisovalerate  | ↓ |  |   | ↑ |   |   |
| 4-hydroxyphenylacetate | ↑ |   |   |   | ↑ |
| 4-pyridoxate |  | ↑ |   |   |   |  |
| Acetate |  |  |   |   |   | ↑ |
| Acetoacetate | ↑ |  | ↑ |   |   |  |
| Acetone |  | ↑ |   |   |   | ↑ |
| Acetylated compounds | ↑ |  |   |   |   |   |
| Alanine |  |  | ↓ | ↑ | ↑ | ↑ |
| Aminobutyrate |  | ↑ |   |   |   |   |
| Arginine |  |  |   |   |   | ↑ |
| Ascorbate |  |  |   | ↓ |   |   |
| Asparagine |  |  | ↓ |   |   |   |
| Betaine |  |  |   |   |   | ↑ |
| Choline |  | ↑ | ↓ |   |   |  |
| Cis-aconitate |  | ↑ | ↑ |   |   |   |
| Citrate | ↓ |  |   | ↓ |   |   |
| Creatinine | ↓ |  | ↓ | ↓ |   |  |
| Cysteine |  |  | ↓ |   |   |  |
| Dimethylamine |  | ↑ |   |   | ↓ |  |
| Dimethyl sulfone |  |  | ↓ |   |   |   |
| Formate |  |  |   |   | ↑ | ↑ |
| Fucose |  | ↑ |   |   |   |   |
| Glucose | ↑ | ↑ |   |   |   |   |
| Glutamine |  |  | ↑ |   |   |  |
| Glycerol |  |  |   | ↓ |   |  |
| Glycine | ↓ |  |   |   |   | ↑ |
| Glycolate |  |  |   |   |   | ↑ |
| Guanido-acetate |  |  | ↑ |   |   |  |
| Hippurate | ↓ |  | ↓ | ↓ |   |   |
| Histidine |  |  |   |   |   | ↑ |
| Homocysteine |  |  | ↑ |   |   |  |
| Hypoxanthine |  | ↑ |   |   |   | ↓ |
| Indoxyl sulfate |  |  |   |   |   | ↑ |
| Isocitrate |  |  | ↓ |   |   |   |
| Lactate |  |  |   |   |   | ↑ |
| Leucine | ↑ |  |   |   |   | ↑ |
| Mannitol |  |  |   |   |   | ↑ |
| Methanol |  | ↓ |   |   |   |  |
| Methionine |  |  |   |   |   | ↑ |
| Methylamine |  |  | ↓ |   |   |   |
| N-acetyl serotonin |  |  |   |   | ↑ |   |
| N-methyl hydantoin |  |  |   |   |   | ↑ |
| O-acetyl carnitine |  | ↑ |   |   |   | ↑ |
| Phenylacetyl glycine |  |  |   |   |   | ↑ |
| Phenylalanine |  |  | ↓ |   |   | ↑ |
| Putrescine |  |  |   |   |   | ↑ |
| Succinate |  |  |   |   |   | ↑ |
| Sucrose |  |  |   |   | ↑ |   |
| Taurine |  | ↑ |   | ↑ |   | ↑ |
| Threonine |  |  |   | ↓ |   |  |
| Threonine |  | ↑ |   |   |   |   |
| TMAO |  | ↑ |   |   |   |   |
| Trans-aconitate |  | ↑ | ↑ |   | ↑ |   |
| Trigonelline | ↓ | ↓ |   |   |   |  |
| Tryptophan |  | ↑ |   |   |   |   |
| Tyrosine |  |  |   |   |   | ↑ |
| Urea |  |   |   | ↑ |   |   |
| Valine |  |  |   |   |   | ↑ |
| Xylose |  | ↑ |   |   |   |  |

1↑Higher metabolite levels in gastrointestinal cancers. 2↓Lower metabolite levels in gastrointestinal cancers. U: Urine; TMAO: Trimetlylamine oxide; CRC: Colorectal cancer; PC: Pancreatic cancer.

**Table 4Panel of altered metabolites’ levels identified in fecal water samples of gastrointestinal cancer patients versus healthy controls**

|  |  |
| --- | --- |
|  | **Fw** |
| **CRC[83]** | **CRC[84]** | **CRC[86]** | **CRC[85]** |
| 4-aminohippurate |  |  | ↓2 |  |
| acetate | ↓ | ↓ |  | ↓ |
| alanine |  | ↑1 | ↓ | ↑ |
| beta-alanine |  |   | ↓ |  |
| butyrate | ↓ | ↓ |   | ↓ |
| cholate |  |  | ↓ |  |
| deoxycholate |  |  | ↓ |  |
| galactose |  |  | ↓ |  |
| glucose |  | ↓ | ↓ |  |
| glutamate |  | ↑ |  | ↑ |
| glutamine |  | ↓ | ↓ |  |
| glycerol |  |  | ↓ |  |
| hexose-phosphate |  |  | ↑ |  |
| isobutyrate |   |   | ↑ |   |
| isoleucine |  | ↑ | ↓ | ↑ |
| isovalerate |   |   | ↑ |   |
| lactate |  | ↑ |  | ↑ |
| leucine | ↑ | ↑ |  | ↑ |
| litho deoxycholate |  |  | ↓ |  |
| methanol |  |  | ↓ |  |
| ornithine |  |  | ↓ |  |
| phenylacetate |  |  |   |  |
| proline | ↑ | ↑ |   |  |
| propionate |  | ↓ |   | ↓ |
| succinate |  | ↑ |   | ↑ |
| taurine |  |  | ↓ |  |
| valine |  | ↑ |   | ↑ |
| xylose |  |  | ↓ |  |

1↑Higher metabolite levels in gastrointestinal cancers. 2↓Lower metabolite levels in gastrointestinal cancers. Fw: Fecal water; CRC: Colorectal cancer.